Defiance Next Gen Altered Experience ETF
Not enough financial coverage to compute a composite score for PSY. This is typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available data still render below.
Company
The index is a rules-based index that tracks the performance of a portfolio of companies conducting legal activities under the national laws of the applicable country related to medical psychedelics, medical cannabis, cannabis pharmaceuticals and cannabidiol derivatives, and ketamine. The fund uses a “replication” strategy to achieve its investment objective, it will invest in all of the component securities of the index in the same approximate proportions as in the index. It is non-diversified.
- IPO
- 2021
- HQ
- DE, US
Price Chart
Performance & Tape
- 52W High
- $5.92
- 52W Low
- $5.84
- 50D MA
- $5.90
- 200D MA
- $5.90
- Beta
- 0.00
- Avg Volume
- 0
Get TickerSpark's AI analysis on PSY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 10, 12 | ROBARDS KAREN P | other | 690 |
| Dec 10, 12 | KESTER W CARL | other | 100 |
| Dec 10, 12 | Harris Jerrold B | other | 161 |
| Dec 10, 12 | CAVANAGH RICHARD | other | 100 |
| Dec 10, 12 | GABBAY HENRY | other | 100 |
| Dec 10, 12 | BASSAS STEPHAN | other | 1,000 |
| Dec 5, 12 | KESTER W CARL | sell | 6,196.02 |
| Dec 5, 12 | CAVANAGH RICHARD | sell | 6,489.78 |
| Dec 5, 12 | HUBBARD ROBERT GLENN | sell | 9,682.1 |
| Dec 5, 12 | ROBARDS KAREN P | sell | 5,726.35 |
Our PSY Coverage
We haven't published any research on PSY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PSY Report →